Duragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist

Similar documents
HYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.

Pre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None

MORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)

90 dosage units per 90 days OR. Extended-release Formulations Ultram ER 90 dosage units per 90 days OR

Levorphanol. Levorphanol Tartrate. Description

Butrans (buprenorphine patch) Description. Section: Prescription Drugs Effective Date: October 1, 2017

Duragesic patch. Duragesic patch (fentanyl patch) Description

Belbuca (buprenorphine buccal film) Belbuca (buprenorphine buccal film) Description

Duragesic patch. Duragesic patch (fentanyl patch) Description

Embeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description

BELBUCA (buprenorphine buccal film)

Hysingla ER. Hysingla ER (hydrocodone bitartrate) Description

Levorphanol. Levorphanol Tartrate. Description

Nucynta IR. Nucynta IR (tapentadol immediate-release) Description

Xartemis XR (oxycodone / acetaminophen extended release)

Belbuca (buprenorphine buccal film) Description. Section: Prescription Drugs Effective Date: October 1, 2016

OXYCODONE IR (oxycodone)

Duragesic patch. Duragesic patch (fentanyl patch) Description. Section: Prescription Drugs Effective Date: January 1, 2019

Demerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description

Oxycodone. Oxycodone IR, Oxycodone ER, OxyContin, Xtampza ER. Description

Targiniq ER (oxycodone/naloxone extended-release), Troxyca ER (oxycodone /naltrexone extended-release)

RATIONALE FOR INCLUSION IN PA PROGRAM

Morphine IR Hydromorphone IR Oxymorphone IR. Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone),

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM

Methadone. Description

Methadone. Description

Morphine Sulfate Hydromorphone Oxymorphone

Morphine Sulfate Hydromorphone Oxymorphone

Extended Release Opioid Drugs

Extended Release Opioid Drugs

Extended Release Opioid Drugs

Background Apadaz (benzhydrocodone-acetaminophen), codeine-acetaminophen, dihydrocodeine-caffeineacetaminophen,

Medications and Children Disorders

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Major Depressive Disorder

USF Health Psychiatry Clinic. New Patient Questionnaire Adult

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

Appendix: Psychotropic Medication Reference Tables

Medications Guide: Public Speaking And Social Anxiety

U T I L I Z A T I O N E D I T S

Dealing with a Mental Health Crisis

Study Guidelines for Quiz #1

PATIENT FACE SHEET PATIENT NAME: PATIENT DOB: PATIENT PHONE #: INSURANCE: MEMBER ID: GROUP NUMBER: PATIENT ADDRESS

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

Objectives: Lifetime prevalence. Neurotransmitters of interest

Treatment of Major Depressive Disorder

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

MAJOR DEPRESSION CLINICAL PRACTICE GUIDELINE

POSITIVE YOUTH CONCEPTS Child and Adolescent Therapy 24 Front Street, Suite 302 Exeter, NH

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Psychiatric Evaluation Intake Form

Drug Effectiveness Review Project (DERP) Summary Report on Second-Generation Antidepressants and Antidepressants Literature Scan

Guide to Psychiatric Medications for Children and Adolescents

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

Psychiatric Evaluation Intake Form

Bridges to Excellence Depression Care Recognition Program Guide

PSYCHIATRIC HISTORY 6. Are you currently seeing a therapist? (Name & contact phone#)

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.

mood treatment center.com brain art from Hope Street Mental Health Greeting cards (hopestreetcards.com.au)

Clinical Policy: Vilazodone (Viibryd) Reference Number: CP.PMN.145 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

9/17/2015 DIAGNOSTIC PUZZLES LEARNING OBJECTIVES MENTAL ILLNESS MEDICAL COMORBIDITIES

Mental Health Medications. National Institute of Mental Health. U.S. Department of HealtH and HUman ServiceS National Institutes of Health

Briefly state the reason for this evaluation: Patient s Name: Sex: Male/Female (circle one) Date of Birth: Age: Patient s Social Security #

CENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG NAME. Use Brand Only

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011

See Important Reminder at the end of this policy for important regulatory and legal information.

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010

Clinical Policy: Levomilnacipran (Fetzima) Reference Number: HIM.PA.125 Effective Date: Last Review Date: 11.18

MO Medicaid Foster Care Drugs FY10-FY14

Before you try another medication, try asking your DNA

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Objectives. Diagnostic Criteria DSM 5. Before we begin I should tell you that. General Diagnostics for Anxiety Disorders 08/02/2014

Antidepressant Agents Step Therapy and Quantity Limit Program Summary

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA

Psychobiology Handout

Available Strengths Limits. 10 mg tablet -- $ mg tablet -- $ mg tablet -- $ mg tablet -- $72.41 Avoid use in members over

AHCCCS BEHAVIORAL HEALTH DRUG LIST EFFECTIVE OCTOBER 1, 2016

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Monoamine oxidase inhibitors (MAOIs) have wellestablished

Use Brand Only. Preferred Drug Status PRIOR AUTHORIZATION REQUIRED

Trintellix dose it cause weight gain

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

CENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG CLASS

Anxiety. Definition. Sometimes anxiety results from a medical condition that needs treatment. Whatever form of anxiety you have, treatment can help.

PSYCHIATRY INTAKE FORM

Steps for Initiating Electroconvulsive Therapy Treatment

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

Tranylcypromine. Why is this medication prescribed? How should this medicine be used? 1 of 5 7/6/ :31 PM. (tran il sip' roe meen) Warning

Patients considering TMS Therapy

The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Mental Health MEDICATION INFORMATION MANUAL

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychopharmacological Management of Depressive and Anxiety Disorders

Transcription:

Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have the following: 1. Pain, severe enough to require daily, around-the clock long term opioid treatment AND ALL of the following: a. If adequate pain control cannot be achieved using a 72-hour regimen, an increase in the dose has been evaluated before changing dosing intervals in order to maintain patients on a 72- hour regimen. b. Prescriber has considered the risks of opioid/substance abuse or addiction in the patient. c. NO dual therapy with other long action opioid analgesic(s) d. Alternative treatment options have been ineffective, not tolerated or inadequate for controlling the pain i. These include non-opioid analgesic and immediate release opioids e. Prescriber agrees to assess the benefits of pain control (i.e. Care Plan signs of abuse, severity of pain) after 3 months of therapy f. Prescriber agrees to assess patient for serotonin syndrome g. NO dual therapy with opioid addiction treatment or methadone h. NO dual therapy with an anti-anxiety benzodiazepine(s) i. Alprazolam (Xanax) ii. Clonazepam (Klonopin) iii. Diazepam (Valium) iv. Lorazepam (Ativan)

Prior - Approval Limits v. Oxazepam (Serax) vi. Chlordiazepoxide (Librium) vii. Clorazepate dipotassium (Tranxene) Dosage Change every 72 hours 12.5 mcg: 30 Patches / 90 days 25 mcg: 30 Patches / 90 days 37.5 mcg: 30 Patches / 90 days 50 mcg: 30 Patches / 90 days 62.5 mcg: 30 Patches / 90 days 75 mcg: 30 Patches / 90 days 87.5 mcg: 30 Patches / 90 days 100 mcg: Up to 90 Patches / 90 days Maximum 3 day (72 hr) limit of any combination: 300mcg Duration Change every 48 hours 12.5 mcg: 45 Patches / 90 days 25 mcg: 45 Patches / 90 days 37.5 mcg: 45 Patches / 90 days 50 mcg: 45 Patches / 90 days 62.5 mcg: 45 Patches / 90 days 75 mcg: 45 Patches / 90 days 87.5 mcg: 45 Patches / 90 days 100 mcg: Up to 135 Patches / 90 days Maximum 2 day (48 hr) limit of any combination: 300mcg 12 months Prior Approval Renewal Requirements Age 2 years of age or older Diagnosis Patient must have the following:

1. Pain, severe enough to require daily, around-the clock long term opioid treatment AND ALL of the following: a. NO dual therapy with other long acting opioid analgesic(s) b. Prescriber agrees to assess the benefits of pain control (i.e. Care Plan signs of abuse, severity of pain) after 3 months of therapy c. Prescriber agrees to assess patient for serotonin syndrome d. NO dual therapy with opioid addiction treatment or methadone e. NO dual therapy with an anti-anxiety benzodiazepine(s) i. Alprazolam (Xanax) ii. Clonazepam (Klonopin) iii. Diazepam (Valium) iv. Lorazepam (Ativan) v. Oxazepam (Serax) vi. Chlordiazepoxide (Librium) vii. Clorazepate dipotassium (Tranxene) Prior Approval Renewal Limits Dosage Change every 72 hours 12.5 mcg: 30 Patches / 90 days 25 mcg: 30 Patches / 90 days 37.5 mcg: 30 Patches / 90 days 50 mcg: 30 Patches / 90 days 62.5 mcg: 30 Patches / 90 days 75 mcg: 30 Patches / 90 days 87.5 mcg: 30 Patches / 90 days 100 mcg: Up to 90 Patches / 90 days Maximum 3 day (72 hr) limit of any combination: 300mcg Change every 48 hours 12.5 mcg: 45 Patches / 90 days 25 mcg: 45 Patches / 90 days 37.5 mcg: 45 Patches / 90 days 50 mcg: 45 Patches / 90 days 62.5 mcg: 45 Patches / 90 days

75 mcg: 45 Patches / 90 days 87.5 mcg: 45 Patches / 90 days 100 mcg: Up to 135 Patches / 90 days Maximum 2 day (48 hr) limit of any combination: 300mcg Duration 12 months

Appendix 1 - List of Serotonergic Medications Selective Serotonin Reuptake Inhibitors (SSRIs) paroxetine Paxil, Paxil CR, Pexeva, Brisdelle fluvoxamine Luvox, Luvox CR fluoxetine Prozac, Prozac Weekly, Sarafem, Selfemra, Symbyax sertraline Zoloft citalopram Celexa escitalopram Lexapro Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) venlafaxine Effexor XR desvenlafaxine Pristiq, Khedezla duloxetine Cymbalta milnacipran Savella Tricyclic Antidepressants (TCAs) amitriptyline No brand name currently marketed desipramine Norpramin clomipramine Anafranil imipramine Tofranil, Tofranil PM nortriptyline Pamelor, Aventyl protriptyline Vivactil doxepin Zonalon, Silenor trimipramine Surmontil Monoamine Oxidase Inhibitors (MAOIs) isocarboxazid Marplan phenelzine Nardil selegiline Emsam, Eldepryl, Zelapar tranylcypromine Parnate Other Psychiatric Medicines amoxapine No brand name currently marketed maprotiline No brand name currently marketed nefazodone No brand name currently marketed trazodone Oleptro buspirone No brand name currently marketed vilazodone Viibryd

mirtazapine llthium Remeron, Remeron Soltab Lithobid Migraine Medicines almotriptan Axert frovatriptan Frova naratriptan Amerge rizatriptan Maxalt, Maxalt-MLT sumatriptan Imitrex, Imitrex Statdose, Alsuma, Sumavel Dosepro, Zecuity, Treximet zolmitriptan Zomig, Zomig-ZMT Antiemetics ondansetron granisetron dolasetron palonosetron Zofran, Zofran ODT, Zuplenz Kytril, Sancuso Anzemet Aloxi Other Serotonergic Medicines dextromethorphan linezolid cyclobenzaprine methylene blue St. John s wort tryptophan Bromfed-DM, Delsym, Mucinex DM, Nuedexta Zyvox Amrix